Cargando…
Clinically relevant drug interactions with multikinase inhibitors: a review
Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. Although the oral route of administration offers improved flexibility and convenience for the patient, challenges arise in the use of MKIs. A...
Autores principales: | Hussaarts, Koen G. A. M., Veerman, G. D. Marijn, Jansman, Frank G. A., van Gelder, Teun, Mathijssen, Ron H. J., van Leeuwen, Roelof W. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322107/ https://www.ncbi.nlm.nih.gov/pubmed/30643582 http://dx.doi.org/10.1177/1758835918818347 |
Ejemplares similares
-
The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019) -
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
por: van Leeuwen, Roelof W. F., et al.
Publicado: (2017) -
Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2021) -
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
por: van Leeuwen, R W F, et al.
Publicado: (2013) -
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019)